Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-1 in Fibromyalgia
NCT01850420Phase 2Completed
- Sponsor
- Dogwood Therapeutics, Inc.
- Start
- May 2013
- Primary completion
- Jan 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of famciclovir and celecoxib in fibromyalgia (FM) (2 arms), sponsored by Dogwood Therapeutics, Inc. Primary endpoint: Change in pain from baseline at 16 weeks. Started May 2013; status: completed.
02
Drugs
famciclovircelecoxib
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT01850420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850420.